Biological Agent Switching in Patients With Juvenile Idiopathic Arthritis: A Tertiary Center Experience.

OBJECTIVE The purpose of this study is to investigate the causes and outcomes of switching biological agents in juvenile idiopathic arthritis (JIA) patients using biological agents and compare the characteristics of patients whose biological agents are switched and those whose are not. METHODS This medical records review study was conducted with 128 patients who were diagnosed with JIA at our clinic between January 2009 and January 2022 and were receiving biologic agents. Factors affecting the biologic agent switching were investigated. RESULTS The JIA subtype with the most frequent switching in biological agents was systemic JIA (n = 13, 40.6%). Systemic JIA was followed by rheumatoid factor-negative polyarticular JIA and persistent oligoarticular JIA with 5 patients (15.6%), extended oligoarticular JIA and enthesitis-related JIA with 3 patients (9.3%), rheumatoid factor-positive polyarticular JIA with 2 patients (6.2%), and undifferentiated JIA with 1 patient (3.1%). Among the patients, 32 (25%) patients had their biological agent switched once, and 5 (3.9%) had theirs switched twice. The most frequently used biological agent was etanercept (n = 76, 59.3%), whereas the most frequently observed cases of biological agent switching were from an anti-TNF agent to another anti-TNF agent (40.6%). The reason for switching was unresponsiveness to the agent in 22 patients (68.8%), adverse effects in 6 patients (18.7%), drug intolerance in 1 patient (3.1%), and other reasons in 3 patients (9.3%). CONCLUSIONS The most frequently used biological agent was etanercept; the most frequent cases of biological agents switching were from an anti-TNF agent to another anti-TNF agent.

[1]  Rahime Koç,et al.  Approach to switching biologics in juvenile idiopathic arthritis: a real-life experience , 2021, Rheumatology International.

[2]  S. Ringold,et al.  Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry , 2020, The Journal of Rheumatology.

[3]  C. Pavesio,et al.  A review of ocular adverse events of biological anti-TNF drugs , 2020, Journal of Ophthalmic Inflammation and Infection.

[4]  W. Thomson,et al.  Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study , 2020, The Lancet Rheumatology.

[5]  R. Cimaz,et al.  Current and emerging biologics for the treatment of juvenile idiopathic arthritis , 2020, Expert opinion on biological therapy.

[6]  R. Schneider,et al.  2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‐Systemic Polyarthritis, Sacroiliitis, and Enthesitis , 2019, Arthritis care & research.

[7]  M. Gattinara,et al.  Biologics for the Treatment of Juvenile Idiopathic Arthritis. , 2019, Current medicinal chemistry.

[8]  S. Kamphuis,et al.  Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries , 2018, Arthritis Research & Therapy.

[9]  I. Olivieri,et al.  Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. , 2018, Rheumatology.

[10]  P. Quartier.  Choice of biologic drug among children with juvenile idiopathic arthritis. , 2016, Rheumatology.

[11]  W. Thomson,et al.  Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers , 2016, Rheumatology.

[12]  K. Barut,et al.  Treatment in juvenile rheumatoid arthritis and new treatment options. , 2015, Turk pediatri arsivi.

[13]  K. Minden,et al.  Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry , 2014, Arthritis & rheumatology.

[14]  E. Haddad,et al.  The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort , 2014, Annals of the rheumatic diseases.

[15]  P. Boracchi,et al.  Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients. , 2014, Reumatismo.

[16]  C. Wouters,et al.  Effect of Biologic Treatments on Growth in Children with Juvenile Idiopathic Arthritis , 2014, The Journal of Rheumatology.

[17]  P. Nigrovic,et al.  2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. , 2013, Arthritis and rheumatism.

[18]  W. Thomson,et al.  Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis , 2012, Annals of the rheumatic diseases.

[19]  K. Armon,et al.  Defining Juvenile Idiopathic Arthritis Remission and Optimum Time for Disease-Modifying Anti-Rheumatic Drug Withdrawal , 2012, Pediatric Drugs.

[20]  A. Martini,et al.  Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis , 2012, The Journal of Rheumatology.

[21]  T. Kishimoto,et al.  Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis , 2012, Modern rheumatology.

[22]  J. Wajdula,et al.  Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan , 2012, Modern rheumatology.

[23]  M. Gattinara,et al.  [Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis]. , 2011, Reumatismo.

[24]  M. Beresford,et al.  Juvenile Idiopathic Arthritis , 2011, Paediatric drugs.

[25]  Alberto Martini,et al.  2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features , 2011, Arthritis care & research.

[26]  S. Kamphuis,et al.  Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register , 2009, Annals of the rheumatic diseases.

[27]  M. Beresford,et al.  New advances in the management of juvenile idiopathic arthritis—2: The era of biologicals , 2009, Archives of Disease in Childhood: Education & Practice Edition.

[28]  M. Gattinara,et al.  Focus on adverse events of tumour necrosis factor α blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients , 2007, Annals of the rheumatic diseases.

[29]  M. Suarez‐Almazor,et al.  International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 , 2004 .

[30]  K. Minden,et al.  Health care provision in pediatric rheumatology in Germany--national rheumatologic database. , 2002, The Journal of rheumatology.

[31]  A. Reiff,et al.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. , 2000, The New England journal of medicine.

[32]  K. Haines.  Juvenile idiopathic arthritis: therapies in the 21st century. , 2007, Bulletin of the NYU hospital for joint diseases.

[33]  C. Wallace,et al.  Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. , 1991, Rheumatic diseases clinics of North America.